BioWorld Asia

May 25, 2011

View Archived Issues

Membrane Receptors Will Open Door to Drug Discovery

EMA Follows FDA Line on Huntexil Development Path

Oxford Biomedica's Parkinson's Drug Improves Motor Function

Spinnovator Raises $56M for New German Start-ups

Going Global: Takeda Paying $13.7B Cash for Nycomed

Shire Acquires Advanced BioHealing for $750M

Other News To Note

GenKyoTex's $20.4M Series C Funds NOX Inhibitor Progress

LONDON – GenKyoTex SA raised CHF18 million (US$20.4 million) in a Series C round, enabling it to take the lead product to the point where it is ready to deliver proof of concept for the company's NOX enzyme inhibition technology. (BioWorld International) Read More

Evotec Shares Fall with Terminated Roche Alliance

Today's news in brief

BioWorld

BioWorld briefs for June 10, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for June 9, 2026

3D rendering of β2-Adrenergic receptor GPCR protein molecule embedded in lipid bilayer membrane.

Skape Bio unlocks GPCR targets with de novo-designed miniproteins

BioWorld

Modulating G protein-coupled receptors (GPCRs) is one of the major challenges in biomedicine. These are flexible proteins with small, deep binding pockets. The...

Antares Therapeutics divulges new CDK2/cyclin E1 inhibitors

BioWorld Science

Antares Therapeutics Inc. has reported new CDK2/cyclin E1 inhibitors potentially useful for the treatment of cancer.

Empire Discovery Institute, Univ. of Rochester identify IRAK inhibitors

BioWorld Science

Empire Discovery Institute and the University of Rochester have discovered new interleukin-1 receptor-associated kinase 1 (IRAK-1) and/or IRAK-4 inhibitors...